Clinical Trial Update: Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) [EARLY_Phase 1]

View source ↗

Summary

Feasibility study of Suizenji in unresectable pancreatic ductal adenocarcinoma (SUNRISE-II) is an early-phase trial currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Suizenji

Snippet

Sponsor: SONIRE Therapeutics Inc. | Conditions: Pancreatic Cancer | EARLY_Phase 1 | Status: RECRUITING